Literature DB >> 11015293

Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1.

J J Maguire1, R E Kuc, A P Davenport.   

Abstract

We have determined the distribution of receptors for human urotensin-II (U-II) in human and rat CNS and peripheral tissues. In rat, [(125)I]-U-II binding density was highest in the abducens nucleus of brainstem (139.6+/-14 amol mm(-2)). Moderate levels were detected in dorsal horn of spinal cord and lower levels in aorta (22. 5+/-6 amol mm(-2)). In human tissues density was highest in skeletal muscle and cerebral cortex ( approximately 30 amol mm(-2)), with lower levels (<15 amol mm(-2)) in kidney cortex and left ventricle. Little binding was identified in atria, conducting system of the heart and lung parenchyma. Receptor density was less in human coronary artery smooth muscle (14.6+/-3 amol mm(-2), n=10) than rat aorta with no significant difference between normal and atherosclerotic vessels. In human skeletal muscle [(125)I]-U-II bound to a single receptor population with K(D)=0.24+/-0.17 nM and B(max)=1.97+/-1.1 fmol mg(-1) protein (n=4). U-II contracted human coronary, mammary and radial arteries, saphenous and umbilical veins with sub-nanomolar EC(50) values. U-II was 50 times more potent in arteries and <10 times more potent in veins than endothelin-1 (ET-1). The maximum response to U-II ( approximately 20% of control KCl) was significantly less than to ET-1 ( approximately 80% KCl). In contrast, in rat aorta, U-II and ET-1 were equipotent with similar maximum responses. This is the first report of high affinity receptors for [(125)I]-U-II in human CNS and peripheral tissues. This peptide produces potent, low efficacy, vasoconstriction in human arteries and veins. These data suggest a potential role for U-II in human physiology.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11015293      PMCID: PMC1572358          DOI: 10.1038/sj.bjp.0703601

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  26 in total

1.  Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction.

Authors:  H P Nothacker; Z Wang; A M McNeill; Y Saito; S Merten; B O'Dowd; S P Duckles; O Civelli
Journal:  Nat Cell Biol       Date:  1999-10       Impact factor: 28.824

2.  Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord.

Authors:  Y Coulouarn; I Lihrmann; S Jegou; Y Anouar; H Tostivint; J C Beauvillain; J M Conlon; H A Bern; H Vaudry
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

3.  Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors.

Authors:  A Marchese; M Heiber; T Nguyen; H H Heng; V R Saldivia; R Cheng; P M Murphy; L C Tsui; X Shi; P Gregor
Journal:  Genomics       Date:  1995-09-20       Impact factor: 5.736

4.  Differential distribution of endothelin peptides and receptors in human adrenal gland.

Authors:  A P Davenport; S L Hoskins; R E Kuc; C Plumpton
Journal:  Histochem J       Date:  1996-11

5.  Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14).

Authors:  M Mori; T Sugo; M Abe; Y Shimomura; M Kurihara; C Kitada; K Kikuchi; Y Shintani; T Kurokawa; H Onda; O Nishimura; M Fujino
Journal:  Biochem Biophys Res Commun       Date:  1999-11       Impact factor: 3.575

6.  Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14.

Authors:  R S Ames; H M Sarau; J K Chambers; R N Willette; N V Aiyar; A M Romanic; C S Louden; J J Foley; C F Sauermelch; R W Coatney; Z Ao; J Disa; S D Holmes; J M Stadel; J D Martin; W S Liu; G I Glover; S Wilson; D E McNulty; C E Ellis; N A Elshourbagy; U Shabon; J J Trill; D W Hay; E H Ohlstein; D J Bergsma; S A Douglas
Journal:  Nature       Date:  1999-09-16       Impact factor: 49.962

7.  Differential distribution of angiotensin AT2 receptors in the normal and failing human heart.

Authors:  J Wharton; K Morgan; R A Rutherford; J D Catravas; A Chester; B F Whitehead; M R De Leval; M H Yacoub; J M Polak
Journal:  J Pharmacol Exp Ther       Date:  1998-01       Impact factor: 4.030

8.  Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors.

Authors:  Y Coulouarn; S Jégou; H Tostivint; H Vaudry; I Lihrmann
Journal:  FEBS Lett       Date:  1999-08-20       Impact factor: 4.124

Review 9.  Novel GPCRs and their endogenous ligands: expanding the boundaries of physiology and pharmacology.

Authors:  A Marchese; S R George; L F Kolakowski; K R Lynch; B F O'Dowd
Journal:  Trends Pharmacol Sci       Date:  1999-09       Impact factor: 14.819

10.  ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro.

Authors:  J J Maguire; A P Davenport
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

View more
  51 in total

1.  Urotensin-II in systemic sclerosis: a new peptide in pathogenesis.

Authors:  Yavuz Pehlivan; Ahmet Mesut Onat; Gazi Comez; Taner Babacan
Journal:  Clin Rheumatol       Date:  2011-01-28       Impact factor: 2.980

Review 2.  Cardiovascular actions of human urotensin II--considerations for hypertension.

Authors:  Fraser D Russell; Peter Molenaar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-19       Impact factor: 3.000

3.  Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis.

Authors:  Arnold S Kristof; Zhipeng You; Yin-Shan Han; Adel Giaid
Journal:  Peptides       Date:  2010-04-28       Impact factor: 3.750

4.  Investigation of the association between Rho/Rho-kinase gene polymorphisms and systemic sclerosis.

Authors:  Yavuz Pehlivan; Servet Yolbas; Gozde Yıldırım Cetin; Fatma Alibaz-Oner; Yonca Cagatay; Neslihan Yilmaz; Serdar Oztuzcu; Salim Donmez; Metin Ozgen; Suleyman Serdar Koca; Omer Nuri Pamuk; Mehmet Sayarlıoglu; Bunyamin Kisacik; Haner Direskeneli; Abdullah Tuncay Demiryurek; Ahmet Mesut Onat
Journal:  Rheumatol Int       Date:  2015-11-28       Impact factor: 2.631

5.  In vitro siRNA-mediated knockdown of the UT receptor: implications of density on the efficacy of a range of UT ligands.

Authors:  Benjamin D Hunt; Leong L Ng; David G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-06       Impact factor: 3.000

6.  Does cigarette smoking increase plasma urotensin II concentrations?

Authors:  S J Gold; J P Thompson; J P Williams; E E F Helm; J Sadler; W Song; L L Ng; D G Lambert
Journal:  Eur J Clin Pharmacol       Date:  2007-01-25       Impact factor: 2.953

7.  Cardiostimulant effects of urotensin-II in human heart in vitro.

Authors:  F D Russell; P Molenaar; D M O'Brien
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

8.  Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats.

Authors:  S M Gardiner; J E March; P A Kemp; A P Davenport; T Bennett
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

9.  A new ligand for the urotensin II receptor.

Authors:  Valeria Camarda; Remo Guerrini; Evi Kostenis; Anna Rizzi; Girolamo Calò; Almut Hattenberger; Marina Zucchini; Severo Salvadori; Domenico Regoli
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

10.  Vasoconstrictive effects of endothelin-1, endothelin-3, and urotensin II in isolated perfused human lungs and isolated human pulmonary arteries.

Authors:  R T Bennett; R D Jones; A H Morice; C F C Smith; M E Cowen
Journal:  Thorax       Date:  2004-05       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.